Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report [PDF]
ESC Heart Failure, 2023 Intravenous (i.v.) prostacyclin is the cornerstone treatment in high‐risk pulmonary arterial hypertension (PAH) patients. Selexipag is an orally available prostacyclin receptor agonist.
André Alexandre +7 more
doaj +2 more sources
Epoprostenol for very low birth weight (VLBW) infants: a novel dilution protocol
La Pediatria Medica e Chirurgica, 2013 Epoprostenol has been the first effective treatment for severe pulmonary arterial hypertension. Epoprostenol is provided in vials for adult therapy. To our knowledge there are no reports on specific dilution protocols for epoprostenol in VLBW infants ...
S. Rugolotto +5 more
doaj +2 more sources
Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
European Respiratory Review, 2017 Epoprostenol was the first therapy to be approved for the treatment of pulmonary arterial hypertension (PAH). In the 20 years since the introduction of this prostacyclin analogue, the outlook for patients with PAH has improved, with survival rates now ...
Olivier Sitbon, Anton Vonk Noordegraaf
doaj +2 more sources
Animals, 2022 Prostacyclin is an in vivo bioactive substance that regulates renal blood flow (RBF). Information regarding how epoprostenol, a prostacyclin preparation, affects RBF in dogs is lacking.
Kiwamu Hanazono +6 more
doaj +2 more sources
Epoprostenol sodium for treatment of pulmonary arterial hypertension
Vascular Health and Risk Management, 2015 Yukihiro Saito,1 Kazufumi Nakamura,1 Satoshi Akagi,1 Toshihiro Sarashina,1 Kentaro Ejiri,1 Aya Miura,1 Aiko Ogawa,2 Hiromi Matsubara,2 Hiroshi Ito1 1Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and ...
Saito Y +8 more
doaj +1 more source
Intravenous epoprostenol therapy in the treatment of pulmonary arterial hypertension in Singapore
Annals, Academy of Medicine, SingaporePulmonary arterial hypertension (PAH) is a progressive disease characterised by significant morbidity and mortality. Intravenous (IV) epoprostenol (Veletri, Johnson & Johnson, US), a prostacyclin analogue, has been shown to improve exercise tolerance ...
Jack Choo +7 more
doaj +2 more sources
Drug Design, Development and Therapy, 2012 Olivier Lambert, Dirk BandillaActelion Pharmaceuticals Ltd, Allschwil, SwitzerlandBackground: The aim of this study was to evaluate the stability and microbiological properties of a formulation of epoprostenol sodium with L-arginine and sucrose ...
Lambert O, Bandilla D
doaj +1 more source
Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
American Journal of Perinatology Reports, 2013 Background Pulmonary arterial hypertension carries a high risk of mortality in pregnancy. Recent advances in treatment may improve disease course and allow for successful management of the pregnancy.
Julia Timofeev +3 more
doaj +2 more sources
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted [PDF]
Drug Design, Development and Therapy, 2012 Olivier Lambert1, Dirk Bandilla1, Rupa Iyer2, Leonore Witchey-Lakshmanan3, Nagesh Palepu41Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; 2TPM Laboratories Inc, Cherry Hill, NJ, USA; 3Pharma CMC/IP, Piscataway, NJ, USA; 4SciDose LLC, Amherst, MA ...
Lambert O +4 more
doaj +1 more source
Comment on "Survival Improvement With Steroid Use for Pulmonary Veno-Occlusive Disease With the Aid of Pulmonary Vasodilators and Tyrosine-Kinase Inhibitor, a Retrospective Study". [PDF]
Clin CardiolClinical Cardiology, Volume 49, Issue 8, August 2026.
Khan W, Khan MF, Khan R.
europepmc +2 more sources